Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Profit After Tax (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Profit After Tax readings, the most recent being $63.7 million for Q1 2026.

  • On a quarterly basis, Profit After Tax rose 12.33% to $63.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $221.3 million, a 12.15% increase, with the full-year FY2025 number at $214.3 million, up 30.78% from a year prior.
  • Profit After Tax hit $63.7 million in Q1 2026 for Catalyst Pharmaceuticals, up from $52.7 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $63.7 million in Q1 2026 to a low of -$30.8 million in Q3 2023.
  • Median Profit After Tax over the past 5 years was $37.8 million (2023), compared with a mean of $35.1 million.
  • Biggest five-year swings in Profit After Tax: tumbled 235.24% in 2023 and later surged 242.65% in 2024.
  • Catalyst Pharmaceuticals' Profit After Tax stood at $25.5 million in 2022, then surged by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then decreased by 5.79% to $52.7 million in 2025, then grew by 20.94% to $63.7 million in 2026.
  • The last three reported values for Profit After Tax were $63.7 million (Q1 2026), $52.7 million (Q4 2025), and $52.8 million (Q3 2025) per Business Quant data.